Jorge Beirão Seixas

Jorge Seixas is an MD, PhD and Tropical Medicine specialist with clinical field experience in Brazil, Guinea-Bissau, Angola and in the Democratic Republic of Congo, as well as travel medicine and tropical medicine practice in Lisbon. Since 1991 he has been teaching at the Institute of Hygiene and Tropical Medicine (IHMT), Lisbon, at post-graduate level. He organized and implemented several courses on Tropical Medicine in Angola and Brazil. He was a member of the Ethical Committee of the IHMT between 2010 and 2014.

For the last 20 years his main focus of research activities has been in Human African Trypanosomiasis (HAT, sleeping sickness), including several implementation and monitoring missions on HAT clinical studies and trials.

His main research interests are presently in Travel Medicine, Neglected Tropical Diseases, on the diagnosis and treatment of malaria, sleeping sickness and Chagas disease, on bioethics and clinical research in developing countries.

He collaborates with WHO on HAT and on Chagas Disease. He is a member of the European Network for Tropical Medicine and Travel Health and of the Portuguese Travel Medicine Society.

Investigator in the DNDi promoted and EDCTP founded project “Towards an arsenic-free oral treatment for human African trypanosomiasis due to T.b. rhodesiense as a tool for disease elimination“. Start: September 2018.

Investigator in the DNDi promoted and EDCTP founded project “Towards a pediatric indication for children between 1 and 14 years of age for a safe, effective, all-oral single-dose treatment formulation of acoziborole for first and second stage gambiense human African trypanosomiasis (g-HAT)”.

Start: march 2021.

1. Lutje V, Probyn K, Seixas J, Bergman H, Villanueva G. Chemotherapy for second-stage human African trypanosomiasis: drugs in use.Cochrane Database of Systematic Reviews (2021), Issue 12. Art. No.: CD015374. DOI: 10.1002/14651858.CD015374.
2. Seixas J, Atouguia J, Josenando T, Vatunga G, Bilenge CMM, Lutumba P, Burri C. (2020) Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association. Trop Med Infect Dis. 2020 Jan 1;5(1). pii: E5. doi: 10.3390/tropicalmed5010005.
3. Antunes ML, Seixas J, Humberto E, Sousa, M. Adequacy of Severe Malaria Markers and Prognostic Scores in an Intensive Care Unit in Luanda, Angola: A Clinical Study. (2020),  Clin. Med. 2020 9(12), 3862; https://doi.org/10.3390/jcm9123862.
4. Lindner A, Lejon V, Chappuis F, Seixas J, Kazumba L, Barret M, et al. (2019). New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis. https://doi.org/10.1016/ S1473-3099(19)30612-7.
5. Parreira R, Conceição C, Centeno-Lima S, Marques N, Saraiva da Cunha J, Abreu C, Sá L, Sarmento A, Atouguia J, Moneti V, Azevedo T, Nina J, Mansinho K, Antunes A, Teodósio R, Nazareth T, Seixas J. (2014) Angola’s 2013 dengue outbreack, clinical, laboratory and molecular analysis of cases from four Portuguese institutions. Infect Dev Ctries. 12;8(9):1210-5.